# A Study to Assess the Safety and Efficacy of IC265 Ophthalmic Solution for Dry Eye in Adult Participants

> **NCT05992922** · PHASE2 · TERMINATED · sponsor: **Iacta Pharmaceuticals** · enrollment: 40 (actual)

## Conditions studied

- Dry Eye Syndromes

## Interventions

- **DRUG:** IC265 Ophthalmic Solution 1%
- **DRUG:** Placebo Ophthalmic Solution (Vehicle)

## Key facts

- **NCT ID:** NCT05992922
- **Lead sponsor:** Iacta Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-10-17
- **Primary completion:** 2023-12-19
- **Final completion:** 2023-12-19
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Unexpected adverse events were observed in a subset of patients on drug. In an over abundance of caution the study was terminated. All adverse events resolved with no sequelae.
- **Last updated:** 2025-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05992922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05992922, "A Study to Assess the Safety and Efficacy of IC265 Ophthalmic Solution for Dry Eye in Adult Participants". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05992922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*